SCHEMBL4488016

SCHEMBL4488016

Cc1[nH]c(C)c(-c2c[nH]c(-c3ccccc3Cl)cc2=O)c(=O)c1Br

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.39
GAA P10253 2/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
PIM1 P11309 1/20 0.38
TNKS2 Q9H2K2 1/20 0.36
SLC2A1 P11166 1/20 0.34
POLB P06746 3/20 0.34
KDM4E B2RXH2 2/20 0.34
TP53 P04637 1/20 0.34
HSP90AA1 P07900 1/20 0.32
PTGES O14684 1/20 0.31
AURKA O14965 1/20 0.31
AURKB Q96GD4 1/20 0.31
KMT2A Q03164 2/20 0.31
PIK3C3 Q8NEB9 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GLA P06280 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4473579 0.88 PIM1 (0.41) BRD4GAALMNATSHRHTT
SCHEMBL4486516 0.86 ADORA2A (0.41) TNKS2SLC2A1HSP90AA1AURKAAURKB
SCHEMBL4490476 0.84 SLC2A1 (0.38) BRD4GAALMNAPIM1SLC2A1
SCHEMBL4487870 0.83 SLC2A1 (0.40) BRD4GAALMNATSHRHTT
SCHEMBL4489339 0.83 SLC2A1 (0.41) SLC2A1PTGESPIK3C3
SCHEMBL4484311 0.81 BRD4 (0.38) BRD4GAAHTTSLC2A1KMT2A
SCHEMBL4464654 0.78 ADORA2A (0.39) TNKS2SLC2A1KDM4EKMT2AMEN1
SCHEMBL4490983 0.76 ADORA2A (0.41) GAALMNATSHRHTTPIM1
SCHEMBL4487288 0.76 PTGS2 (0.39) BRD4SLC2A1
SCHEMBL4479166 0.75 TYMP (0.34) SLC2A1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US claimed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US claimed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP claimed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO claimed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP BRD4 2655/4885GAA 2573/4885LMNA 2161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.